Oral Session 2-9B CML: Clinical trials

[OS2-9B-3] Analysis of cardiovascular risk factors in nilotinib-treated Japanese CML patients

Isao Fujioka¹, Tomoiku Takaku¹, Michihide Tokuhira², Yuta Kimura², Eisaku Iwanaga³, Keiji Sugimoto⁴, Tomonori Nakazato⁵, Noriyoshi Iriyama⁶, Eriko Sato⁷, Maho Ishikawa⁸, Hiroyuki Fujita⁹, Norio Asou⁸, Yoshihiro Hatta⁶, Masahiro Kizaki², Norio Komatsu¹, Tatsuya Kawaguchi¹⁰ (1.Dept. Hematology, Juntendo University School of Medicine, Tokyo, Japan, 2.Dept. Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, 3.Dept. Hematology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan, 4.Dept. Hematology, Juntendo University Urayasu Hospital, Urayasu, Japan, 5.Dept. Hematology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan, 6.Div. Hematology & Rheumatology, Nihon University School of Medicine, Tokyo, Japan, 7.Div. Hematology, Dept. Medicine, Juntendo University Nerima Hospital, Tokyo,, 8.Hemato-Oncology, Comprehensive Cancer Center, Saitama Medical University International Medical Center, 9.Dept. Hematology, Saiseikai Yokohama Nanbu Hospital, Yokohama, Japan, 10.Kumamoto Health Science University, Kumamoto, Japan)